In MS, CXCL12 presumably plays both anti-inflammatory as protective effects as it is associated with redistribution of perivascular CXCL12 via ACKR3 from the basolateral to the luminal side of the blood brain barrier during disease onset but also with later induction of remyelination and regulatory T cells [10]. Here, CXCL12 is linked to myeloid sarcoma.